Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14006091 | 0.92 | ALDH1A1 (0.61) | CYP2C19CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL14006088 | 0.84 | HDAC1 (0.58) | CYP2C19CYP1A2CYP2D6ALDH1A1CD274 | |
| SCHEMBL8480165 | 0.82 | ALDH1A1 (0.66) | CYP2C19CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL14385089 | 0.81 | ALDH1A1 (0.77) | ALDH1A1HSD17B10MAPTHPGDKDM4E | |
| SCHEMBL29626496 | 0.81 | HDAC1 (0.56) | CYP2C19CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL29037358 | 0.81 | HDAC1 (0.56) | CYP2C19CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL6015767 | 0.81 | POLB (0.60) | CYP2C19CYP1A2CYP2D6ALDH1A1CD274 | |
| SCHEMBL30265188 | 0.81 | POLB (0.60) | CYP2C19CYP1A2CYP2D6ALDH1A1CD274 | |
| SCHEMBL18845433 | 0.80 | CYP2C19 (0.78) | CYP2C19CYP1A2CYP2D6ALDH1A1CD274 | |
| SCHEMBL8479110 | 0.79 | ALDH1A1 (0.62) | CYP2C19CYP1A2CYP2D6ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7572806-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572806-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7491831-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-0850220-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | CYP2C19 971/4885CYP1A2 2176/4885CYP2D6 1798/4885 |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | CYP2C19 1356/4885CYP1A2 1147/4885CYP2D6 1489/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | CYP2C19 1356/4885CYP1A2 1147/4885CYP2D6 1489/4885 |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | CYP2C19 1356/4885CYP1A2 1147/4885CYP2D6 1489/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | CYP2C19 16/4885CYP1A2 111/4885CYP2D6 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.